Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.
about
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Digital logic circuits in yeast with CRISPR-dCas9 NOR gatesTailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.Is autoimmunity the Achilles' heel of cancer immunotherapy?T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.CAR T-cell therapy of solid tumors.Immune targets and neoantigens for cancer immunotherapy and precision medicine.The Principles of Engineering Immune Cells to Treat Cancer.Methods to investigate the structure and connectivity of the nervous system.Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.Development of CAR T cells designed to improve antitumor efficacy and safety.Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.Cytoskeletal control of B cell responses to antigens.Reprogramming cellular functions with engineered membrane proteins.Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.Development of an optimized synthetic Notch receptor as an in vivo cell-cell contact sensor.Practical considerations for chimeric antigen receptor design and delivery.Regulation of T cell proliferation with drug-responsive microRNA switches.Notch Signaling in Development, Tissue Homeostasis, and Disease.Prospects for combined use of oncolytic viruses and CAR T-cells.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?Nonimmune cells equipped with T-cell-receptor-like signaling for cancer cell ablation.Safety strategies of genetically engineered T cells in cancer immunotherapy.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models.Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors.Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.Synthetic biology: Sensing with modular receptors.Biologics: Engineering T cells for customized therapeutic responses.Reverse and forward engineering of protein pattern formation.Notable advances 2016.Engineering Axl specific CAR and SynNotch receptor for cancer therapy.Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.Versatile CAR T-cells for cancer immunotherapy.CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell GrowthImmunological-based approaches for cancer therapyCheckpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine GliomasPrecision medicine in pediatric oncology
P2860
Q34548319-88B54E2D-8731-40FF-87BD-6323B603278CQ36379818-B3F66FBC-AE56-46DD-965F-4035F4E37D96Q38677432-E824B4B2-F40C-4058-B51C-7176DE8ED26CQ38687375-A8D0ABB1-0C11-4E76-8A0C-5D383C926EF0Q38873974-EDE0AA36-5BEE-4CD9-9035-41117A62848BQ39047856-F013EDF0-D906-4756-AACA-F560B0C416D6Q39057617-1A42EF20-C442-4823-827D-84F4858F9CBFQ39130457-21B6D958-A4F5-4E3D-92AD-CB040B865DBBQ39170983-A70EE699-1C19-40FA-A019-2405DC7D8CA7Q39178061-95E9621F-B71B-499A-A23E-677B46CEE855Q39200527-E78308F5-A2C1-4C17-9A65-0CB47CC07296Q39256918-BC21B653-C42D-48C6-8521-49D2BE48264EQ39264898-B0D2D91D-3642-41EB-A3CA-0E9EE52AA007Q39424290-7A43EA26-EF54-44DF-BE1F-DFE631975625Q39435526-E1C28021-7D5C-4772-9D66-A58A11CE7495Q41664346-7AD39785-DF50-4C33-A207-B5E2FD93C813Q45141397-B448D6B8-0710-454D-9A80-15071330087EQ45868559-6ADF29AB-B30F-44E0-8084-61F32E2CA232Q45950927-604C534A-9E79-42DE-BC83-B5CD444EFCFEQ46795621-5369BDCC-93EE-4FE9-8980-3FDDE77622C9Q47103891-7342514B-001B-49DE-B7FE-9B5252D7D619Q47110966-13D521BD-CA14-4F1A-938F-A72EACCA2EEAQ47285613-3E4527F1-8737-4787-8561-84CB414D85ADQ47355616-6E692612-CC43-4EE3-9E13-92B06943927AQ47667620-8963A798-A146-4FF5-821F-2666DFEACB63Q49280922-D59EF6BE-4559-464B-B489-FBF920111A54Q49477144-B186EE1D-2850-421F-BF17-2239B8AFEAD6Q50035774-AC677198-806E-4E9B-A3C1-E89200216FADQ50531950-DC4BF59E-E9A6-405D-96E1-E4DC9DB42308Q51037564-C2098B1E-BD8A-49F6-8136-650DF89A8C59Q51091767-355C5BDB-B49B-4B2C-B8BE-1AC9E28120EDQ52327488-A8187900-6DA8-4A2B-8072-0629B25BEC71Q52426493-499BD260-84D9-4C14-99FE-BD66AD1B93F7Q54123522-D69A0A49-3253-44D7-B8AC-A2FAF4730B1BQ55216327-670C8C15-B68A-4AC6-96F9-8E5626E643BFQ55347731-63D9DCD9-6B38-4869-AD97-34D94F1936D2Q57158297-371FF35F-B167-4790-9AAC-C7254904D4BDQ57168423-65B069AF-4BE1-4B6E-A011-31A81C6C75FCQ57300937-462F7390-682B-41D2-A4ED-9E874E22206FQ57384544-30DD5561-6277-45B9-8D8A-4AB56900C286
P2860
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Engineering T Cells with Custo ...... ing Synthetic Notch Receptors.
@en
type
label
Engineering T Cells with Custo ...... ing Synthetic Notch Receptors.
@en
prefLabel
Engineering T Cells with Custo ...... ing Synthetic Notch Receptors.
@en
P2093
P2860
P1433
P1476
Engineering T Cells with Custo ...... ing Synthetic Notch Receptors.
@en
P2093
Isabel Kolinko
Jasper Z Williams
Joseph H Choe
Kole T Roybal
Krista A McNally
Leonardo Morsut
Levi J Rupp
Wendell A Lim
Whitney J Walker
P2860
P304
419-432.e16
P356
10.1016/J.CELL.2016.09.011
P407
P577
2016-09-28T00:00:00Z